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Introduction
In the last few years, increasing evidence suggests that 
circulating tumor cells (CTCs) play a principal role in 
dissemination from primary tumors in the generation of 
distant metastases (1).
CTCs can be isolated from blood in a non-invasive 
approach and can be used to follow patients over time 
since these cells can provide significant information 
for a better understanding of tumor biology and tumor 
dissemination (2). Several methods have been developed 
to detect and isolate CTCs from the peripheral blood 
of patients with cancer (3). To date, CellSearch® System 
(Janssen Diagnostics, LLC, Raritan, NJ, USA) is the only 
Food and Drug Administration (FDA) approved method 
used to obtain prognostic information through CTC 
counts. The system performs automated immunomagnetic 
ephitelial  cell  adhesion molecule (EpCAM) based 
enrichment followed by cytokeratins (CK) staining of 
cells in blood samples (4). In the last years, evidence is 
emerging regarding a possible drug-related impairment in 
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the predictive value of CTCs during treatment. Specifically, 
data from literature show that CTC count through 
CellSearch® in metastatic breast and colorectal cancer 
(CRC) patients treated with bevacizumab (BEV) retains a 
significant prognostic value at baseline but lacks predictive 
significance as an early surrogate marker of response when 
assessed under treatment (5,6).
It is also hypothesized that BEV (I) may generate in the 
primary tumor a selected population of cells undergoing 
epithelial to mesenchymal transition (EMT) (6); this process 
evokes a change from a polarized epithelial phenotype, in 
which cells are adherent to the basement membrane and 
express classical epithelial markers including EpCAM, to 
a mesenchymal state in which cell-cell contact is lost and 
mesenchymal markers are expressed; markers of EMT 
program include downregulation of CK, E-cadherin and 
β-catenin and upregulation of N-cadherin and vimentin (7); 
(II) may act directly on the tumor cells (5), in same way 
modifying the EpCAM expression through not still 
established mechanisms. Therefore a different EpCAM 
isoform expression might be responsible for failure of 
CellSearch® System to detect CTCs, since isolation and 
detection of CTC with immunomagnetic enrichment 
methods is critically dependent on the used EpCAM clone (8).
In order to verify these hypotheses, in the present 
preliminary study we sought to investigate whether chronic 
exposure to BEV at clinically relevant doses (9) may alter 
proteins involved in EMT (CK, E-cadherin, N-cadherin, 
β-catenin, vimentin) or alternatively may induce EpCAM 
modifications in human CRC cell lines in vitro. The ability 
of CellSearch® to capture BEV-treated cells has been also 
investigated.
Materials and methods
Antibodies
Antibodies for western blot and immunofluorescence 
analysis were as follows: monoclonal mouse anti-EpCAM, 
monoclonal mouse anti-vimentin, monoclonal mouse anti-
β-catenin, polyclonal rabbit anti-N-cadherin, monoclonal 
mouse anti-E-cadherin (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA) and monoclonal mouse anti-
cytokeratin 8, 18, 19 (Abcam, Cambridge, MA, USA).
Cell lines and culture conditions
WiDr human CRC cell line was obtained from Interlab Cell 
Line Collection (Genova, GE, Italy). Cell line was cultured 
in minimal essential medium (MEM) supplemented with 
10% fetal bovine serum (FBS) (SIGMA-ALDRICH, St. 
Louis, MO, USA), penicillin-streptomycin, L-glutamine 
and non essential amino acids (EuroClone S.P.A., Pero, MI, 
Italy) at 37 ℃ in 5% CO2 and 95% air.
The human CRC cell line WiDr was exposed to a 
clinically relevant dose of BEV (250 μg/mL) for 3 months 
in vitro. Results from all in vitro studies were confirmed in at 
least three independent experiments to verify results. All the 
experiments were performed when cells reached 50-60% 
confluence.
Untreated WiDr cells were used as a control.
Protein extraction and western blot
Cells were washed twice with cold PBS, collected and 
centrifuged at 400 g for 10 min. Cell pellets were solubilised 
in 10 mM Tris-HCl pH 7.6, 160 mM NaCl, 1 mM EGTA, 
1% deoxycholic acid, 1% Triton, 0.1% SDS and one 
complete mini-protease inhibitor cocktail tablet (SIGMA 
Chemicals Company, St. Louis. MO, USA), incubated 
on ice for 30’ and centrifuged at 12,000 g for 30 min; the 
supernatant was then collected.
Protein extracts (30 µg) were incubated at 100 ℃ for 
10 min and separated on 4-12% SDS-PAGE gel, blotted 
onto PVDF membrane (GE Healthcare, Milano, Italy) and 
probed with primary antibodies overnight at 4 ℃.
The next day, they were washed three times for 10 min 
with TBS and 0.1% Tween-20 and re-probed with 
the appropriate secondary antibody for 1 h at room 
temperature.
After incubation and three washes, immunoreactive 
bands were visualized by enhanced chemoluminescence 
(PerkinElmer, Waltham, MA, USA).
Mouse anti-actin (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) served as a protein loading control.
Results were confirmed in at least three independent 
experiments to verify results.
Immunofluorescence
Cells, grown on coverslips, untreated and treated as 
described above, were fixed with 4% paraformaldehyde in 
PBS for 30 min, washed in 0.1 M glycine for 20 min, and 
permeabilized in 0.1% Triton X-100 for additional 5 min.
After blocking for 5 min with 1% BSA cells were 
incubated with the following primary antibodies and 
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visualized using FITC-conjugated goat anti-mouse IgG 
fluorescein isothiocyanate-conjugated (Alexa 488, Life 
Technologies) for additional 30 min at room temperature. 
The nuclei were stained with 4,6-diamido-2-phenylindole 
(DAPI, Sigma-Aldrich, Milan, Italy).
Cells were analyzed using an Apotome Axio Observer 
Z1 inverted microscope (Zeiss, Oberkochen, Germany), 
equipped with an AxioCam MRM Rev.3 at 40× magnification. 
Image analysis was performed using Adobe Photoshop.
All experiments included negative controls with 
secondary antibody alone.
Results were confirmed in at least three independent 
experiments to verify results.
WiDr detection by CellSearch® System
To evaluate the impact of chronic exposure to BEV on 
CTC enumeration by CellSearch®, untreated and BEV-
treated colon cancer cell (WiDr) were spiked into blood 
samples from a healthy volunteer. Four experiments have 
been performed: before treatment (time 0), and in course of 
treatment (1, 2, 3 months). A defined number (50 individual 
cells) was collected by pipetting under microscopic control 
and directly transferred into the blood sample which was 
then processed by CellSearch®.
Results were confirmed in at least three independent 
experiments to verify results.
Results
To study the effects of chronic BEV exposure on CRC 
cells, the expression of epithelial and mesenchymal markers 
were determined by immunofluorescence and western 
blot in untreated and BEV-treated cell lines after 1, 2 and 
3 months of exposure. At 1 and 2 months after treatment no 
differences were observed between untreated and treated 
cells, neither at immunofluorescence nor at western blot 
analysis (data not shown).
At three months of treatment, immunofluorescence 
analysis showed that BEV neither altered the expression 
of vimentin and N-cadherin (both absent in untreated and 
treated cells), nor that of E-cadherin, EpCAM and β-catenin 
(unchanged in untreated and treated cells), but induced a 
weak decrease in the expression of CK (Figure 1).
Western blot analysis confirmed that E-cadherin and 
β-catenin levels did not change in treated cells compared 
to untreated cells, whereas CK expression decreased in 
treated cells. Vimentin and N-cadherin were also found 
undetectable in both untreated and treated cell lines. 
Interestingly, it revealed in treated WiDr cell lines a 
significant increase of EpCAM 42 kDa isoform expression 
and a concomitant decrease of EpCAM 40 kDa isoform, 
compared to controls (Figure 2).
To evaluate the impact of EpCAM variant isoforms 
expression on CTC enumeration by CellSearch®, 
50 untreated cells and 50 BEV treated colon cancer cells 
(1, 2, 3 months) were spiked into 7.5 mL of blood from 
an healthy donor and enumerated by CellSearch®. The 
recovery rate of cells through CellSearch® was gradually 
reduced in course of treatment with BEV, being 84%, 70% 
and 40% at 1, 2 and 3 months, respectively (Figure 3).
Discussion
During the last five years, it has been demonstrated 
that BEV combined with chemotherapy may modify 
the predictive value of CTC during treatment. In an 
exploratory prospective substudy reported by Bidard et al. 
in 2010 (5), CTCs were screened by CellSearch® assay in 
patients who received BEV combined with chemoterapy as 
first-line treatment of metastatic breast cancer. CTCs were 
found of prognostic significance for time to progression 
(TTP) and predictive of tumor response at baseline, but not 
6 weeks after the start of the treatment.  Authors 
hypothesized that the lack of CTC significance during 
treatment may be directly related to the systematic use 
of BEV, probably due to its direct anti-CTC effect. 
Alternatively, they also suggested that the use of BEV may 
change the intravasation abilities of cancer cells, due to its 
effect on the vessels endothelium.
Furthermore, in 2011 our group investigated the 
predictive value of CTC count in patients with metastatic 
CRC treated with a first-line chemotherapy plus BEV 
compared with those treated with chemotherapy plus 
cetuximab. CTC count was carried out by CellSearch® 
assay. A total of 56% of patients treated with BEV with 
0 CTC at follow-up evaluation had a progressive disease 
(PD), while in the group treated with cetuximab, patients 
with persistent high CTC count were found in PD and 
patients with decreased number of CTC were found with 
stable disease or partial response. We hypothesized that 
BEV, through the inhibition of tumor angiogenesis and 
consequently the induction of hypoxia, may generate in the 
primary tumor a selected population of cells undergoing 
EMT, which loose cell-cell contact, become motile and 
acquire mesenchymal features (6).
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Figure 1 Immunofluorescence staining of epithelial and mesenchymal markers. Cytokeratins decrease was observed in WiDr cell line under 
bevacizumab exposure but not in untreated cells. EpCAM, β-catenin and E-cadherin remained unchanged in both treated and untreated 
cells. N-cadherin and vimentin were absent in both treated and untreated cells. The blue counterstaining (DAPI) shows the location of 
nuclei. EpCAM, ephitelial cell adhesion molecule.
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To verify this hypothesis, we now sought to investigate 
whether BEV may exert direct effects on CRC cells in vitro 
attributable to the generation of EMT phenotype. To this 
purpose, and due to the difficulty to generate CTC cell 
lines, we used the human colon cancer WiDr cell line to be 
exposed to a clinically relevant dose of BEV.
We failed to find any morphological evidence of EMT 
in vitro, probably due to the necessity of contact with 
endothelial surface or organ systems in vivo, as previously 
suggested (10). Nevertheless, we found that BEV induces a 
decreased expression of CK, strongly evident at 3 months of 
treatment, which may also have impaired CTC enumeration 
through CellSearch®. In congruence with this, Gökmen-
Polar et al. recently demonstrated that in breast cancer BEV 
treatment may result in the deregulation of one or more 
high molecular weight/basal keratins (11). We then sought 
to investigate whether BEV may induce some alteration 
in EpCAM expression, which might account for the lack 
of predictive significance of CellSearch® in colon cancer 
patients treated with antiangiogenic therapy.
We showed for the first time that BEV induces a 
decrease of EpCAM 40 kDa isoform expression and an 
increase of EpCAM 42 kDa isoform expression. We have 
no explanation for the appearance of the 42 kDa EpCAM 
isoform, although we may speculate that one of these would 
be glycosylation. In fact, it has been reported that most 
carcinoma cell lines produce multiple EpCAM isoforms of 
38, 40, 42 kDa as a result of differential glycosylation of the 
polypeptide backbone. Indeed, the sequence of EpCAM 
molecule predicts three potential N-linked glycosylation 
sites (12), and the attached carbohydrates likely contain 
mannose oligosaccharide chains (13). Unfortunately, the 
EpCAM antibody used in the CellSearch® capture system is 
not known, so that our hypothesis remains speculative.
To evaluate the impact of EpCAM variant isoforms 
expression on CTC enumeration by CellSearch®, we have 
spiked untreated and BEV treated colon cancer cell into 
blood samples which were then enumerated. The recovery 
rate of cells through CellSearch® was gradually reduced 
in course of treatment with BEV, being only 40% after 
3 months, concomitant with the strongest decrease of 
EpCAM 40 kDa isoform as demonstrated by Western blot 
analysis. Thus, it is conceivable that BEV may impair CTC 
recovery by CellSearch® not only through the induction 
of EMT, as we had previously hypothesized, but through 
a modulation of EpCAM isoforms. These hypotheses are 
congruent with the results of the study by Antolovic et al., 
who for the first time showed that isolation and detection 
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Figure 2 Western blotting of epithelial and mesenchymal 
markers. The analysis confirms that chronic bevacizumab exposure 
decreases cytokeratins expression. EpCAM 40 kDa decrease and 
EpCAM 42 kDa increase were observed in WiDr cell line at 
3 month of treatment compared with untreated cells. β-catenin 
and E-cadherin remained unchanged in both treated and untreated 
cells. N-cadherin and vimentin were absent in both treated and 
untreated cells. Actin was used for loading control. EpCAM, 
ephitelial cell adhesion molecule.
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Figure 3 EpCAM-based detection of WiDr. Fifty cells were spiked 
in healthy donor blood and enumerated by CellSearch®. The 
recovery rate of cells was gradually reduced in course of treatment 
with bevacizumab, being 84%, 70% and 40% at 1, 2 and 3 months, 
respectively. Untreated cells were used as control. EpCAM, 
ephitelial cell adhesion molecule.
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of CTC with immunomagnetic enrichment methods 
is critically dependent on the used EpCAM clone. The 
dissimilar capture of CTC by two different mAbs in their 
analysis was explained by various expression of the EpCAM 
molecule among the examined patients (8).
BEV-dependent modification of EpCAM and CK 
suggests that EpCAM-based enrichment techniques may 
lead to the failure to detect CTC in BEV treated patients. 
Our findings may explain clinical results where low CTC 
numbers have been reported even in patients with late 
metastatic cancers.
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